Full-spectrum immunocytokine engineering services, offering Fc/Albumin fusion design and strategic selection between monomeric and homodimeric formats to guarantee superior pharmacokinetic (PK) profiles and half-life extension.
Creative Biolabs' IL-21 engineering & application development services are dedicated to overcoming the inherent liabilities of native IL-21 for research and therapeutic development. We provide comprehensive, customized engineering solutions, including IL-21 mutein design, half-life extension via Fc-fusion or PEGylation, and advanced integration into ACT platforms. Our clients gain a mechanistically validated, preclinically de-risked lead candidate with enhanced efficacy and safety profiles, accelerating their transition from discovery to advanced research.
Interleukin-21 (IL-21) is a critical cytokine for boosting anti-tumor immunity by activating cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. However, native IL-21 suffers from rapid clearance and pleiotropic effects, limiting its translational potential. Successful therapeutic development requires precision engineering to overcome these limitations. Creative Biolabs' services focus on generating attenuated, tumor-targeted IL-21 variants that dramatically widen the research window for cytokine applications.
For an in-depth analysis of how our services can help with your specific project, schedule your free consultation.
Fig.1 Interleukin-21-targeted immune cells. 1
Full-spectrum immunocytokine engineering services, offering Fc/Albumin fusion design and strategic selection between monomeric and homodimeric formats to guarantee superior pharmacokinetic (PK) profiles and half-life extension.
Rigorous functional validation through proprietary bioassays (STAT3 phosphorylation, NK cytotoxicity, T-cell proliferation) and robust mechanism of action (MoA) elucidation for accelerated regulatory filing.
A consultative, one-stop service covering molecular design, expression, high-purity purification, functional assay validation, and PK modeling for all IL-21 therapeutic modalities.
This service transforms short-lived IL-21 into long-acting, precision-targeted therapeutics. We use Fc/Albumin fusions, immunocytokine design, and structural optimization to ensure superior PK and localized immune activation for your research.
Our team has a deep, validated understanding of IL-21 receptor kinetics, molecular structure, and the complex immunobiology required for successful therapeutic manipulation.
We provide a seamless transition between molecular engineering, bioassay development, and process scalability, ensuring your candidate is scientifically robust from day one.
Every data package and report is structured with a "lead-generation mindset," providing clear, compelling evidence that accelerates your research documentation and funding rounds.
We move beyond wild-type cytokines, applying expertise in creating and testing attenuated muteins to solve the fundamental safety challenges that plague native cytokine research.
Experience the Creative Biolabs advantage - get a quote today.
A Native IL-21, even in combination, suffers from poor PK properties and potential systemic toxicity, which limits the dose you can safely give. Our engineered muteins and targeted immunocytokines (like anti-PD-1/IL-21 fusions) solve this by extending half-life and localizing activity, providing a much wider therapeutic window and a higher probability of translational success.
A We use structure-guided design to create highly attenuated variants, which significantly reduce non-specific binding while maintaining potent activity on target cells. This functional bias minimizes detrimental side effects like DC suppression, a key liability of native IL-21.
Precision design of IL-2 super-agonists and selectively attenuated IL-2 variants for Treg sparing, maximizing T cell proliferation while minimizing regulatory cell impact.
Learn More →Development of IL-15 Fc-fusions and super-agonists to achieve robust NK cell expansion and superior anti-tumor response in preclinical models.
Learn More →Creative Biolabs enables you to accelerate your IL-21 therapeutic from a potent concept to a mechanistically validated lead candidate with superior efficacy and safety in preclinical models. Our expert team is prepared to guide you through every stage. Please contact us.
Reference